Active Ingredient History
Colesevelam (trade name Welchol) a non-absorbed, polymeric, lipid-lowering agent intended for oral administration. Colesevelam is poly(allylamine hydrochloride) cross-linked with epichlorohydrin and alkylated with 1-bromodecane and (6-bromohexyl)-trimethylammonium bromide. Colesevelam hydrochloride is a hydrophilic, water-insoluble polymer that is not hydrolyzed by digestive enzymes and is not absorbed. Colesevelam is part of a class of drugs known as bile acid sequestrants. Colesevelam hydrochloride, the active pharmaceutical ingredient in Welchol, is a non-absorbed, lipid-lowering polymer that binds bile acids in the intestine, impeding their reabsorption. As the bile acid pool becomes depleted, the hepatic enzyme, cholesterol 7-α-hydroxylase, is upregulated, which increases the conversion of cholesterol to bile acids. This causes an increased demand for cholesterol in the liver cells, resulting in the dual effect of increasing transcription and activity of the cholesterol biosynthetic enzyme, HMG-CoA reductase, and increasing the number of hepatic LDL receptors. These compensatory effects result in increased clearance of LDL-C from the blood, resulting in decreased serum LDL-C levels. Colesevelam is indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia as monotherapy and to improve glycemic control in adults with type 2 diabetes mellitus, including in combination with a statin. The expanded use of colesevelam in adults with type 2 diabetes mellitus is an example of drug repositioning. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute-On-Chronic Liver Failure (Phase 2/Phase 3)
Atherosclerosis (Phase 4)
Bile Acids and Salts (Phase 4)
Carotid Artery Diseases (Phase 4)
Coronary Artery Disease (Phase 4)
Crohn Disease (Phase 4)
Diarrhea (Phase 4)
Dyslipidemias (Phase 4)
Fecal Incontinence (Phase 3)
Gastroesophageal Reflux (Phase 3)
Healthy Volunteers (Phase 4)
Hypercholesterolemia (Phase 4)
Hyperglycemia (Phase 4)
Hyperlipidemia, Familial Combined (Phase 4)
Hyperlipidemias (Phase 4)
Hyperlipoproteinemia Type II (Phase 4)
Irritable Bowel Syndrome (Phase 4)
Multiple Myeloma (Phase 2)
Non-alcoholic Fatty Liver Disease (Phase 2)
Obesity, Morbid (Phase 4)
Prediabetic State (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
